Payment overview · 2025
General Payments
$61.21
3 reported records · 2 companies
Healthcare provider profile · identity verified
Zafar Ahmed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CRESTWOOD, IL · NPI 1700872272
Verified facts
What the public records show
CMS Open Payments records show Zafar Ahmed, MD received $61.21 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 68.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 202 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.66 | 68.1% | 2 | 2025 |
| Bioventus LLC | Unresolved — no canonical attribution shown | $19.55 | 31.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.21 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.40 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| EXOGEN ULTRASOUND BONE HEALING SYSTEM Normalized: exogen ultrasound bone healing system |
Device | Bioventus LLC | $19.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 202 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
202 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 193 |
| Amlodipine Besylate | Amlodipine Besylate | 573 | 170 |
| Losartan Potassium | Losartan Potassium | 328 | 103 |
| Gabapentin | Gabapentin | 288 | 88 |
| Hydrochlorothiazide | Hydrochlorothiazide | 285 | 93 |
| Metformin Hcl | Metformin Hcl | 280 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 88 |
| Furosemide | Furosemide | 225 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 203 | 49 |
| Eliquis | Apixaban | 202 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 188 | 48 |
| Potassium Chloride | Potassium Chloride | 183 | 51 |
| Carvedilol | Carvedilol | 169 | 51 |
| Lisinopril | Lisinopril | 168 | 52 |
| Montelukast Sodium | Montelukast Sodium | 167 | 74 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 49 |
| Omeprazole | Omeprazole | 162 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 152 | 64 |
| Hydralazine Hcl | Hydralazine Hcl | 151 | 52 |
| Alprazolam | Alprazolam | 127 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 36 |
| Simvastatin | Simvastatin | 111 | 38 |
| Nifedipine Er | Nifedipine | 102 | 28 |
| Allopurinol | Allopurinol | 98 | 30 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 84 | 30 |
| Famotidine | Famotidine | 83 | 35 |
| Azithromycin | Azithromycin | 81 | 48 |
| Ozempic | Semaglutide | 78 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 27 |
| Januvia | Sitagliptin Phosphate | 75 | 16 |
| Alendronate Sodium | Alendronate Sodium | 74 | 22 |
| Ibuprofen | Ibuprofen | 71 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 19 |
| Solifenacin Succinate | Solifenacin Succinate | 69 | 19 |
| Glipizide | Glipizide | 67 | 22 |
| Tramadol Hcl | Tramadol Hcl | 67 | 23 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 67 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 23 |
| Metformin Hcl Er | Metformin Hcl | 57 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 15 |
| Enalapril Maleate | Enalapril Maleate | 55 | 16 |
| Jardiance | Empagliflozin | 54 | 12 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Spironolactone | Spironolactone | 53 | 14 |
| Levetiracetam | Levetiracetam | 52 | suppressed |
| Baclofen | Baclofen | 51 | 16 |
| Prednisone | Prednisone | 50 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 45 | 12 |
| Clonidine Hcl | Clonidine Hcl | 44 | 17 |
| Aripiprazole | Aripiprazole | 42 | suppressed |
| Meloxicam | Meloxicam | 42 | 11 |
| Warfarin Sodium | Warfarin Sodium | 41 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | 12 |
| Donepezil Hcl | Donepezil Hcl | 39 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Linzess | Linaclotide | 36 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 35 | 11 |
| Lovastatin | Lovastatin | 33 | 14 |
| Heparin Sodium | Heparin Sodium,porcine | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | 13 |
| Topiramate | Topiramate | 32 | suppressed |
| Bumetanide | Bumetanide | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Glipizide Er | Glipizide | 29 | 12 |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Diazepam | Diazepam | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Olanzapine | Olanzapine | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Rexulti | Brexpiprazole | 21 | suppressed |
| Valsartan | Valsartan | 21 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 13 |
| Telmisartan | Telmisartan | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | 15 |
| Folic Acid | Folic Acid | 16 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Nyamyc | Nystatin | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 13 | 12 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Captopril | Captopril | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.21 · 3 records | PFIZER INC. | ABRYSVO, COMIRNATY, ELIQUIS, EXOGEN ULTRASOUND BONE HEALING SYSTEM, NURTEC ODT, PREVNAR 20 | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error